Insider Selling: Belite Bio (NASDAQ:BLTE) CFO Sells $9,275,608.12 in Stock

Posted by Geri Gentry on Sep 12th, 2026

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) CFO Hao-Yuan Chuang sold 49,433 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $187.64, for a total transaction of $9,275,608.12. Following the sale, the chief financial officer owned 44,000 shares of the company’s stock, valued at $8,256,160. This trade represents a 52.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Hao-Yuan Chuang also recently made the following trade(s):

On Tuesday, September 8th, Hao-Yuan Chuang sold 17,962 shares of Belite Bio stock. The shares were sold at an average price of $196.42, for a total value of $3,528,096.04.
On Wednesday, August 12th, Hao-Yuan Chuang sold 367 shares of Belite Bio stock. The shares were sold at an average price of $180.35, for a total value of $66,188.45.

Belite Bio Stock Down 0.7%

BLTE opened at $173.79 on Friday. Belite Bio, Inc. Sponsored ADR has a 52 week low of $64.80 and a 52 week high of $200.00. The business has a 50 day moving average price of $161.66 and a two-hundred day moving average price of $158.79. The company has a market cap of $7.00 billion, a PE ratio of -63.66 and a beta of -1.23.

Belite Bio (NASDAQ:BLTE – Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share for the quarter. As a group, sell-side analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.08 EPS for the current fiscal year.

Institutional Trading of Belite Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Engineers Gate Manager LP grew its position in Belite Bio by 11.4% during the second quarter. Engineers Gate Manager LP now owns 2,773 shares of the company’s stock worth $427,000 after buying an additional 284 shares during the period. Bank of America Corp DE lifted its position in shares of Belite Bio by 104.0% during the 1st quarter. Bank of America Corp DE now owns 3,778 shares of the company’s stock valued at $602,000 after acquiring an additional 1,926 shares during the period. Amundi purchased a new stake in shares of Belite Bio during the 1st quarter worth approximately $671,000. Royal Bank of Canada grew its holdings in shares of Belite Bio by 7.9% in the 1st quarter. Royal Bank of Canada now owns 2,257 shares of the company’s stock worth $360,000 after acquiring an additional 165 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Belite Bio in the 1st quarter worth approximately $3,125,000. Institutional investors and hedge funds own 0.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on BLTE. Truist Financial set a $217.00 price target on shares of Belite Bio in a report on Friday, May 22nd. Zacks Research cut Belite Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a research report on Monday, July 6th. Morgan Stanley raised their price target on Belite Bio from $201.00 to $206.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Finally, UBS Group restated a “buy” rating on shares of Belite Bio in a research note on Thursday, September 3rd. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Belite Bio presently has an average rating of “Moderate Buy” and an average target price of $218.73.

Read Our Latest Research Report on BLTE

About Belite Bio

(Get Free Report)

Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious retinal diseases. The company’s research centers on therapies designed to address the underlying biological processes that contribute to vision loss, including the accumulation of toxic vitamin A–derived compounds in the retina.

Belite Bio’s lead product candidate is tinlarebant, also known as LBS-008. Tinlarebant is an orally administered retinol-binding protein 4 antagonist intended to reduce the delivery of vitamin A to the retina and limit the formation of toxic bisretinoids.